Figure S8 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types

Q: What type of study is this?

This is a Cohort Study study (also classified as: Experimental Study).

Zahra Davoudi; Thomas S. Dexheimer; Nathan P. Coussens; Thomas Silvers; Raymond G. Fox; Samantha B. Kemp; Punita Juneja; Joel Morris; Melinda G. Hollingshead; Naoko Takebe; James H. Doroshow; Beverly A. Teicher

doi:10.1158/2767-9764.30304678

October 8, 2025

Figure S8 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types

View Full Paper

Ask AI

Bookmark

Share

Key Points

Combination treatment with BI-3406 and temuterkib demonstrates significant anti-cancer activity in multicell-type tumor spheroids.
The analysis reveals that treatment effectively targets oncogenic KRAS variants across various cancer types.
Methodology involves assessing combination activity in patient-derived multicell-type tumor spheroids to simulate tumor behavior.
These findings support advancing combination approaches in treating cancers with KRAS mutations; further testing may be warranted.

Implication

Observational analysis shows anti-cancer effects of BI-3406 combined with temuterkib in multicell-type tumor spheroids, highlighting potential treatment avenues.

Abstract

Figure S8. Combination activity of BI-3406 with temuterkib in multicell-type tumor spheroids.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Davoudi et al. (2025) studied this question.

synapsesocial.com/papers/68e861857ef2f04ca37e3bed https://doi.org/10.1158/2767-9764.30304678

View Full Paper

Ask AI

Bookmark

Share

Figure S8 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types

Key Points

Implication

Abstract

Discussion

Cite This Study

Figure S8 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading